Hansoh Pharmaceutical Group Future Growth
Future criteria checks 2/6
Hansoh Pharmaceutical Group is forecast to grow earnings and revenue by 8.7% and 8.9% per annum respectively. EPS is expected to grow by 8.5% per annum. Return on equity is forecast to be 12.8% in 3 years.
Key information
8.7%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals earnings growth | 12.7% |
| Revenue growth rate | 8.9% |
| Future return on equity | 12.8% |
| Analyst coverage | Good |
| Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price
Nov 07Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Oct 11A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 14The Hansoh Pharmaceutical Group (HKG:3692) Share Price Is Up 51% And Shareholders Are Holding On
Jan 31Will Weakness in Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Stock Prove Temporary Given Strong Fundamentals?
Dec 08
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13,825 | 4,509 | 4,189 | 4,459 | 10 |
| 12/31/2025 | 12,480 | 3,753 | 3,912 | 3,677 | 22 |
| 12/31/2024 | 11,818 | 3,742 | 3,539 | 3,283 | 19 |
| 12/31/2023 | 10,104 | 3,278 | 2,754 | 3,116 | N/A |
| 9/30/2023 | 9,782 | 2,926 | 2,292 | 2,615 | N/A |
| 6/30/2023 | 9,459 | 2,575 | 1,830 | 2,114 | N/A |
| 3/31/2023 | 9,421 | 2,579 | 2,140 | 2,427 | N/A |
| 12/31/2022 | 9,382 | 2,584 | 2,449 | 2,741 | N/A |
| 9/30/2022 | 9,675 | 2,652 | 2,646 | 3,004 | N/A |
| 6/30/2022 | 9,968 | 2,720 | 2,842 | 3,267 | N/A |
| 3/31/2022 | 9,952 | 2,717 | 2,472 | 2,922 | N/A |
| 12/31/2021 | 9,935 | 2,713 | 2,102 | 2,577 | N/A |
| 9/30/2021 | 9,524 | 2,675 | 1,415 | 2,345 | N/A |
| 6/30/2021 | 9,112 | 2,638 | 729 | 2,113 | N/A |
| 3/31/2021 | 8,901 | 2,603 | 840 | 2,252 | N/A |
| 12/31/2020 | 8,690 | 2,569 | 951 | 2,390 | N/A |
| 9/30/2020 | 8,377 | 2,526 | 1,775 | 2,802 | N/A |
| 6/30/2020 | 8,063 | 2,483 | 2,600 | 3,213 | N/A |
| 3/31/2020 | 8,373 | 2,520 | 2,666 | 3,271 | N/A |
| 12/31/2019 | 8,683 | 2,557 | 2,732 | 3,330 | N/A |
| 9/30/2019 | 8,615 | 2,357 | 2,529 | 3,092 | N/A |
| 6/30/2019 | 8,548 | 2,157 | 2,325 | 2,854 | N/A |
| 3/31/2019 | 8,135 | 2,030 | 2,008 | 2,463 | N/A |
| 12/31/2018 | 7,722 | 1,903 | 1,690 | 2,072 | N/A |
| 12/31/2017 | 6,186 | 1,595 | 1,139 | 1,402 | N/A |
| 12/31/2016 | 5,433 | 1,476 | N/A | 1,247 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3692's forecast earnings growth (8.7% per year) is above the savings rate (2.2%).
Earnings vs Market: 3692's earnings (8.7% per year) are forecast to grow slower than the Hong Kong market (11.7% per year).
High Growth Earnings: 3692's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3692's revenue (8.9% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 3692's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3692's Return on Equity is forecast to be low in 3 years time (12.8%).